Benvenuti S - Search Results

1

The MET receptor tyrosine kinase in invasion and metastasis.

Benvenuti S, Comoglio PM. Benvenuti S, et al. J Cell Physiol. 2007 Nov;213(2):316-25. doi: 10.1002/jcp.21183. J Cell Physiol. 2007. PMID: 17607709 Review.

2

A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth.

Bardelli A, Longati P, Williams TA, Benvenuti S, Comoglio PM. Bardelli A, et al. Among authors: benvenuti s. J Biol Chem. 1999 Oct 8;274(41):29274-81. doi: 10.1074/jbc.274.41.29274. J Biol Chem. 1999. PMID: 10506185 Free article.

3

Targeting the MET oncogene in cancer and metastases.

Stella GM, Benvenuti S, Comoglio PM. Stella GM, et al. Among authors: benvenuti s. Expert Opin Investig Drugs. 2010 Nov;19(11):1381-94. doi: 10.1517/13543784.2010.522988. Epub 2010 Sep 26. Expert Opin Investig Drugs. 2010. PMID: 20868306 Free article. Review.

4

MET mutations in cancers of unknown primary origin (CUPs).

Stella GM, Benvenuti S, Gramaglia D, Scarpa A, Tomezzoli A, Cassoni P, Senetta R, Venesio T, Pozzi E, Bardelli A, Comoglio PM. Stella GM, et al. Among authors: benvenuti s. Hum Mutat. 2011 Jan;32(1):44-50. doi: 10.1002/humu.21374. Epub 2010 Nov 9. Hum Mutat. 2011. PMID: 20949619 Free article.

5

Ron kinase transphosphorylation sustains MET oncogene addiction.

Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Benvenuti S, et al. Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6. Cancer Res. 2011. PMID: 21212418 Free article.

6

Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis.

Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Gentile A, et al. Among authors: benvenuti s. Cancer Res. 2011 Apr 15;71(8):3132-41. doi: 10.1158/0008-5472.CAN-10-2662. Epub 2011 Apr 12. Cancer Res. 2011. PMID: 21487037 Free article.

7

An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.

Benvenuti S, Gentile A, Lazzari L, Arnesano A, Trusolino L, Comoglio PM. Benvenuti S, et al. Mol Oncol. 2014 Mar;8(2):378-88. doi: 10.1016/j.molonc.2013.12.006. Epub 2013 Dec 18. Mol Oncol. 2014. PMID: 24389243 Free PMC article.

8

The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells.

Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Gentile A, et al. Among authors: benvenuti s. Int J Cancer. 2014 Nov 15;135(10):2305-16. doi: 10.1002/ijc.28879. Epub 2014 Apr 15. Int J Cancer. 2014. PMID: 24706440 Free article.

9

Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Zarei O, Benvenuti S, Ustun-Alkan F, Hamzeh-Mivehroud M, Dastmalchi S. Zarei O, et al. Among authors: benvenuti s. J Cancer Res Clin Oncol. 2016 Dec;142(12):2429-2446. doi: 10.1007/s00432-016-2214-4. Epub 2016 Aug 8. J Cancer Res Clin Oncol. 2016. PMID: 27503093 Review.

10

MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.

Stella GM, Benvenuti S, Gentile A, Comoglio PM. Stella GM, et al. Among authors: benvenuti s. EBioMedicine. 2017 Oct;24:34-42. doi: 10.1016/j.ebiom.2017.09.025. Epub 2017 Sep 21. EBioMedicine. 2017. PMID: 29037604 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

262 results

Search Page